AR and prostate cancer: As another example, prostate cancer is the second leading cause of cancer related deaths in men, and patients who fail Androgen Deprivation Therapy (ADT) often respond well to androgen receptor (AR) signaling inhibitors such as enzalutamide and abiraterone 17.